Increased serum levels of sPD-L1 in cancer patients, compared to healthy individuals, have been reported in e.g., renal cell cancer, hepatocellular cancer, and lung cancer [18,19,20]. This evidence concerns the gene SPDL1 and hepatocellular carcinoma.